Advanced Search

Technical Analysis for RPRX - Royalty Pharma plc

Grade Last Price % Change Price Change
F 42.31 0.88% 0.37
RPRX closed up 0.88 percent on Friday, April 9, 2021, on 37 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.
3 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
Historical RPRX trend table...
Date Alert Name Type % Chg
Cup with Handle Other 0.00%
Outside Day Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Cup with Handle Other 0.88%
Narrow Range Bar Range Contraction 0.88%
NR7 Range Contraction 0.88%
Inside Day Range Contraction 0.88%
Oversold Stochastic Weakness 0.88%
Cup with Handle Other 1.78%
Down 3 Days in a Row Weakness 1.78%
Older End-of-Day Signals for RPRX ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
60 Minute Opening Range Breakout about 23 hours ago
Rose Above Previous Day's High about 23 hours ago
Outside Day about 23 hours ago
Down 1% 1 day ago
Fell Below Previous Day's Low 1 day ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Get Started for Free!
Configure default chart indicators Basic chart:

Profile

Royalty Pharma Plc provides drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. The firm's portfolio includes royalties, including AbbVie and J&J's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Gilead's HIV franchise, Merck's Januvia, Novartis' Promacta, and Vertex's Kalydeco, Symdeko and Trikafta, and four development-stage product candidates. It focuses on acquiring royalty-generating products segment. The firm invests in biopharmaceutical products. The company was founded by Pablo Gerardo Legorreta in 1996 and is headquartered in New York, NY.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Pharmaceutical Pharmaceutical Industry Pharmaceutical Products Drug Development HIV Biopharmaceutical Products Biopharmaceutical Industry Drug Development Services

Is RPRX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

Recent News

Date Title
Apr 8 Dicerna Sells Oxlumo Royalty Interest To Royalty Pharma For $180M Upfront
Apr 8 Royalty Pharma acquires Oxlumo royalty interest from Dicerna
Apr 8 Royalty Pharma Acquires OXLUMO™ Royalty Interest From Dicerna for up to $240 Million
Apr 8 Dicerna Sells OXLUMO™ (lumasiran) Royalty Interest to Royalty Pharma for Up to $240 Million
Apr 1 Royalty Pharma acquires royalty interest in cabozantinib from GSK
Apr 1 Royalty Pharma Acquires Royalty Interest in Cabozantinib From GSK
Mar 30 Royalty Pharma Appoints Henry A. Fernandez as Lead Independent Director
Mar 11 Spot Emerging Growth Stocks Like Upstart, Fiserv By Following The Smart Money
Feb 28 The Past Week's Notable Insider Buys: Agree Realty, Avis Budget, Zoetis And More
Feb 17 Royalty Pharma plc (RPRX) CEO Pablo Legorreta on Q4 2020 Results - Earnings Call Transcript
See more RPRX news...

Indicators

Indicator Value
52 Week High 56.5
52 Week Low 34.8
Average Volume 2,870,954
200-Day Moving Average 44.29
50-Day Moving Average 45.79
20-Day Moving Average 44.29
10-Day Moving Average 42.72
Average True Range 1.50
ADX 20.15
+DI 15.24
-DI 26.25
Chandelier Exit (Long, 3 ATRs ) 44.24
Chandelier Exit (Short, 3 ATRs ) 45.93
Upper Bollinger Band 48.40
Lower Bollinger Band 40.17
Percent B (%b) 0.26
BandWidth 18.59
MACD Line -1.16
MACD Signal Line -1.02
MACD Histogram -0.1404
Fundamentals Value
Market Cap 15.48 Billion
Num Shares 366 Million
EPS -0.62
Price-to-Earnings (P/E) Ratio -68.13
Price-to-Sales 12.88
Price-to-Book 5.94
PEG Ratio -0.02
Dividend 0.60
Dividend Yield 1.42%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 43.77
Resistance 3 (R3) 43.64 43.02 43.52
Resistance 2 (R2) 43.02 42.65 43.08 43.44
Resistance 1 (R1) 42.66 42.42 42.84 42.80 43.36
Pivot Point 42.05 42.05 42.13 42.11 42.05
Support 1 (S1) 41.69 41.67 41.87 41.82 41.26
Support 2 (S2) 41.07 41.45 41.14 41.18
Support 3 (S3) 40.72 41.07 41.10
Support 4 (S4) 40.85